Patent holdings for IPC class A61K 31/38

Total number of patents in this class: 529

10-year publication summary

29
20
30
22
20
20
15
40
19
13
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Principal owners for this class

Owner
All patents
This class
Allergan, Inc.
2356
19
Merck Sharp & Dohme Corp.
2200
8
Shire Human Genetic Therapies, Inc.
190
7
The Regents of the University of California
19857
6
Flatley Discovery Lab, LLC
19
6
Mirum Pharmaceuticals, Inc.
78
6
Gilead Sciences, Inc.
2031
5
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
824
5
Sunshine Lake Pharma Co., Ltd.
596
5
Merck Sharp & Dohme LLC
3751
5
Glaxosmithkline LLC
538
4
Massachusetts Institute of Technology
10030
4
Lumena Pharmaceuticals, Inc.
13
4
Satiogen Pharmaceuticals, Inc.
13
4
University of Notre Dame du Lac
564
4
Sumitomo Dainippon Pharma Oncology, Inc.
18
4
Sitryx Therapeutics Limited
38
4
Vandria SA
15
4
Bristol-myers Squibb Company
4879
3
F. Hoffmann-La Roche AG
7934
3
Other owners 419